PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Elsner, M. ; Rauser, S. ; Maier, S.K. ; Schöne, C. ; Balluff, B. ; Meding, S. ; Jung, G. ; Nipp, M. ; Sarioglu, H. ; Maccarrone, G.* ; Aichler, M. ; Feuchtinger, A. ; Langer, R.* ; Jütting, U. ; Feith, M.* ; Kuster, B.* ; Ueffing, M. ; Zitzelsberger, H. ; Höfler, H. ; Walch, A.K.

MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma.

J. Proteomics 75, 4693-4704 (2012)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
To characterize proteomic changes found in Barrett's adenocarcinoma and its premalignant stages, the proteomic profiles of histologically defined precursor and invasive carcinoma lesions were analyzed by MALDI imaging MS. For a primary proteomic screening, a discovery cohort of 38 fresh frozen Barrett's adenocarcinoma patient tissue samples was used. The goal was to find proteins that might be used as markers for monitoring cancer development as well as for predicting regional lymph node metastasis and disease outcome. Using mass spectrometry for protein identification and validating the results by immunohistochemistry on an independent validation set, we could identify two of 60 differentially expressed m/z species between Barrett's adenocarcinoma and the precursor lesion: COX7A2 and S100-A10. Furthermore, among 22m/z species that are differentially expressed in Barrett's adenocarcinoma cases with and without regional lymph node metastasis, one was identified as TAGLN2. In the validation set, we found a correlation of the expression levels of COX7A2 and TAGLN2 with a poor prognosis while S100-A10 was confirmed by multivariate analysis as a novel independent prognostic factor in Barrett's adenocarcinoma. Our results underscore the high potential of MALDI imaging for revealing new biologically significant molecular details from cancer tissues which might have potential for clinical application. This article is part of a Special Issue entitled: Translational Proteomics.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.878
1.188
57
85
Tags
Icb_biostatistics PROT-CF
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter COX7A2; S100-A10; TAGLN2; MALDI imaging mass spectrometry; Barrett's adenocarcinoma; Carcinogenesis
Sprache
Veröffentlichungsjahr 2012
HGF-Berichtsjahr 2012
ISSN (print) / ISBN 1874-3919
e-ISSN 1876-7737
Zeitschrift Journal of Proteomics
Quellenangaben Band: 75, Heft: 15, Seiten: 4693-4704 Artikelnummer: , Supplement: ,
Verlag Elsevier
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Analytical Pathology (AAP)
Institute of Pathology (PATH)
CF Metabolomics & Proteomics (CF-MPC)
Translational Metabolic Oncology (IDC-TMO)
Institute of Biomathematics and Biometry (IBB)
POF Topic(s) 30205 - Bioengineering and Digital Health
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
30203 - Molecular Targets and Therapies
30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
Forschungsfeld(er) Enabling and Novel Technologies
Radiation Sciences
PSP-Element(e) G-500390-001
G-500300-001
G-505700-001
G-501000-001
G-503800-001
PubMed ID 22365974
DOI 10.1016/j.jprot.2012.02.012
Scopus ID 84864092193
Erfassungsdatum 2012-04-25
[➜Korrektur melden]